BEN signs AI solution deal with top ad agency for pharma client; $250K Q4 rev

Brand Engagement Network Inc.

Agreement with unit of one of world's largest ad holding companies for custom AI solution for top-10 pharma client; parties confidential pending formal release.
Expected $250,000 revenue in Q4 2025 from two Statements of Work; subject to performance and acceptance.
Monthly recurring license fees separate from development anticipated to start in Q1 2026.
CEO highlights progress in healthcare vertical with secure AI for pharma manufacturers, providers, and patients.
Deal builds on BEN's Latin American licensing partnership and Skye Salud healthcare AI platform in Mexico.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Brand Engagement Network Inc. entered into Vendor Services Project Agreement with a leading global advertising and communications agency, a unit of one of the world's largest advertising holding companies (effective 2025-12-19).

Action: entry
Counterparty: a leading global advertising and communications agency, a unit of one of the world's largest advertising holding companies
Effective: 2025-12-19

Exact text from the filing

On December 19, 2025, Brand Engagement Network, Inc. (the “Company” or “BEN”) entered into a Vendor Services Project Agreement with a leading global advertising and communications agency, a unit of one of the world’s largest advertising holding companies

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Brand Engagement Network Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-029157

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.